BioCentury This Week Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
Jan 15, 2026
James Wong, a seasoned venture investor with deep expertise in biotech, discusses China's rapid strides in RNAi and the dynamics of valuation in global markets. Ingrid Yin, co-founder of MayTech Global Investments, shares insights on the public market outlook and the practical impact of AI in biotech. They explore the implications of 'China speed' in clinical trials and the changing landscape for startups, particularly in Japan. The conversation highlights the innovative ecosystems emerging in Asia and how local strategies are shaping the future of healthcare investments.
AI Snips
Chapters
Transcript
Episode notes
China As An RNAi Powerhouse
- China has rapidly become a hotbed for RNAi and other modalities due to speed and strong R&D infrastructure.
- RNAi offers lower-risk, genetically targeted treatments and broad target space, making it strategic for China innovation.
China's Fast, Low-Cost Development Model
- Chinese companies can progress new modalities from discovery to clinic extremely cheaply and fast, sometimes under $2 million per molecule.
- That speed and low cost challenges Western timelines and valuations for early-stage assets.
AI Creates New Bottlenecks, Clinical Trials Loom
- AI is being adopted across discovery to commercial but solving one workflow creates new bottlenecks downstream.
- Clinical trials remain the biggest bottleneck and a major area where AI could deliver value.